Daniel Aletaha

ORCID

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 106

Top Venues

Annals of the rheumatic diseases

RMD open

Arthritis & rheumatology (Hoboken, N.J.)

Rheumatology (Oxford, England)

This page only lists publications with an associated author ORCID identifier.

Publications

Kevin L Winthrop, Philip Mease, Andreas Kerschbaumer, Reinhard E Voll, Ferdinand C Breedveld, Josef S Smolen, Jacques-Eric Gottenberg, Xenofon Baraliakos, Hans P Kiener, Daniel Aletaha, John Dudley Isaacs, Maya H Buch, Mary K Crow, Jonathan Kay, Leslie J Crofford, Ronald F Van Vollenhoven, Caroline Ospelt, Stefan Siebert, Margreet Kloppenburg, Iain B McInnes, Thomas Wj Huizinga, Ellen M Gravallese
Unmet need in rheumatology: reports from the Advances in Targeted Therapies meeting, 2023. Annals of the rheumatic diseases 83 (4) (2024)
Andreas Kerschbaumer, Josef S Smolen, Ricardo Jorge de Oliveira Ferreira, Heidi Bertheussen, Xenofon Baraliakos, Daniel Aletaha, Dennis G McGonagle, Désirée Mfm van der Heijde, Iain B McInnes, Bente Appel Esbensen, Kevin L Winthrop, Wolf-Henning Boehncke, Johan A F Koekkoek, Laure Gossec
Efficacy and safety of pharmacological treatment of psoriatic arthritis: a systematic literature research informing the 2023 update of the EULAR recommendations for the management of psoriatic arthritis. Annals of the rheumatic diseases 83 (6) (2024)
Markus Kieler, Leona Sophia Prammer, Gerwin Heller, Melanie Hofmann, Simon Sperger, Dominik Hanetseder, Birgit Niederreiter, Andrea Komljenovic, Kristaps Klavins, Thomas Köcher, Julia Stefanie Brunner, Irena Stanic, Laura Oberbichler, Ana Korosec, Andrea Vogel, Martina Kerndl, Dominika Hromadová, Laszlo Musiejovsky, Alexander Hajto, Anja Dobrijevic, Tina Piwonka, Arvand Haschemi, Anne Miller, Philippe Georgel, Darja Marolt Presen, Johannes Grillari, Silvia Hayer, Jean-Philippe Auger, Gerhard Krönke, Omar Sharif, Daniel Aletaha, Gernot Schabbauer, Stephan Blüml
Itaconate is a metabolic regulator of bone formation in homeostasis and arthritis. Annals of the rheumatic diseases (2024)
Laure Gossec, Andreas Kerschbaumer, Ricardo Jorge de Oliveira Ferreira, Daniel Aletaha, Xenofon Baraliakos, Heidi Bertheussen, Wolf-Henning Boehncke, Bente Appel Esbensen, Iain B McInnes, Dennis McGonagle, Kevin L Winthrop, Andra Balanescu, Peter V Balint, Gerd-Rüdiger R Burmester, Juan D Cañete, Pascal Claudepierre, Lihi Eder, Merete Lund Hetland, AnnaMaria Iagnocco, Lars Erik Kristensen, Rik Lories, Rubén Queiro, Daniele Mauro, Helena Marzo-Ortega, Phillip J Mease, Peter Nash, Wendy Wagenaar, Laura Savage, Larissa Valor-Méndez, Stephanie J W Shoop-Worrall, Yoshiya Tanaka, Filip E Van den Bosch, Annette van der Helm-van Mil, Alen Zabotti, Désirée Mfm van der Heijde, Josef S Smolen
EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update. Annals of the rheumatic diseases 83 (6) (2024)
Andreas Kerschbaumer, Josef S Smolen, Ricardo Jorge de Oliveira Ferreira, Heidi Bertheussen, Xenofon Baraliakos, Daniel Aletaha, Dennis G McGonagle, Désirée Mfm van der Heijde, Iain B McInnes, Bente Appel Esbensen, Kevin L Winthrop, Wolf-Henning Boehncke, Johan A F Koekkoek, Laure Gossec
Efficacy and safety of pharmacological treatment of psoriatic arthritis: a systematic literature research informing the 2023 update of the EULAR recommendations for the management of psoriatic arthritis. Annals of the rheumatic diseases 83 (6) (2024)
Kevin L Winthrop, Philip Mease, Andreas Kerschbaumer, Reinhard E Voll, Ferdinand C Breedveld, Josef S Smolen, Jacques-Eric Gottenberg, Xenofon Baraliakos, Hans P Kiener, Daniel Aletaha, John Dudley Isaacs, Maya H Buch, Mary K Crow, Jonathan Kay, Leslie J Crofford, Ronald F Van Vollenhoven, Caroline Ospelt, Stefan Siebert, Margreet Kloppenburg, Iain B McInnes, Thomas Wj Huizinga, Ellen M Gravallese
Unmet need in rheumatology: reports from the Advances in Targeted Therapies meeting, 2023. Annals of the rheumatic diseases 83 (4) (2024)
Andreas Kerschbaumer, Josef S Smolen, Ricardo Jorge de Oliveira Ferreira, Heidi Bertheussen, Xenofon Baraliakos, Daniel Aletaha, Dennis G McGonagle, Désirée Mfm van der Heijde, Iain B McInnes, Bente Appel Esbensen, Kevin L Winthrop, Wolf-Henning Boehncke, Johan A F Koekkoek, Laure Gossec
Efficacy and safety of pharmacological treatment of psoriatic arthritis: a systematic literature research informing the 2023 update of the EULAR recommendations for the management of psoriatic arthritis. Annals of the rheumatic diseases 83 (6) (2024)
Laure Gossec, Andreas Kerschbaumer, Ricardo Jorge de Oliveira Ferreira, Daniel Aletaha, Xenofon Baraliakos, Heidi Bertheussen, Wolf-Henning Boehncke, Bente Appel Esbensen, Iain B McInnes, Dennis McGonagle, Kevin L Winthrop, Andra Balanescu, Peter V Balint, Gerd-Rüdiger R Burmester, Juan D Cañete, Pascal Claudepierre, Lihi Eder, Merete Lund Hetland, AnnaMaria Iagnocco, Lars Erik Kristensen, Rik Lories, Rubén Queiro, Daniele Mauro, Helena Marzo-Ortega, Phillip J Mease, Peter Nash, Wendy Wagenaar, Laura Savage, Larissa Valor-Méndez, Stephanie J W Shoop-Worrall, Yoshiya Tanaka, Filip E Van den Bosch, Annette van der Helm-van Mil, Alen Zabotti, Désirée Mfm van der Heijde, Josef S Smolen
EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update. Annals of the rheumatic diseases 83 (6) (2024)
Laure Gossec, Andreas Kerschbaumer, Ricardo Jorge de Oliveira Ferreira, Daniel Aletaha, Xenofon Baraliakos, Heidi Bertheussen, Wolf-Henning Boehncke, Bente Appel Esbensen, Iain B McInnes, Dennis McGonagle, Kevin L Winthrop, Andra Balanescu, Peter V Balint, Gerd-Rüdiger R Burmester, Juan D Cañete, Pascal Claudepierre, Lihi Eder, Merete Lund Hetland, AnnaMaria Iagnocco, Lars Erik Kristensen, Rik Lories, Rubén Queiro, Daniele Mauro, Helena Marzo-Ortega, Phillip J Mease, Peter Nash, Wendy Wagenaar, Laura Savage, Larissa Valor-Méndez, Stephanie J W Shoop-Worrall, Yoshiya Tanaka, Filip E Van den Bosch, Annette van der Helm-van Mil, Alen Zabotti, Désirée Mfm van der Heijde, Josef S Smolen
EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update. Annals of the rheumatic diseases 83 (6) (2024)
Gerd-Rüdiger R Burmester, Jacques-Eric Gottenberg, Roberto Felice Caporali, Kevin L Winthrop, Yoshiya Tanaka, Edmund V Ekoka Omoruyi, Vijay Rajendran, Paul Van Hoek, Katrien Van Beneden, Tsutomu Takeuchi, René Westhovens, Daniel Aletaha
Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years. Annals of the rheumatic diseases 83 (9) (2024)
Gerd-Rüdiger R Burmester, Jacques-Eric Gottenberg, Roberto Felice Caporali, Kevin L Winthrop, Yoshiya Tanaka, Edmund V Ekoka Omoruyi, Vijay Rajendran, Paul Van Hoek, Katrien Van Beneden, Tsutomu Takeuchi, René Westhovens, Daniel Aletaha
Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years. Annals of the rheumatic diseases (2024)
Andreas Kerschbaumer, Josef S Smolen, Ricardo Jorge de Oliveira Ferreira, Heidi Bertheussen, Xenofon Baraliakos, Daniel Aletaha, Dennis G McGonagle, Désirée Mfm van der Heijde, Iain B McInnes, Bente Appel Esbensen, Kevin L Winthrop, Wolf-Henning Boehncke, Johan A F Koekkoek, Laure Gossec
Efficacy and safety of pharmacological treatment of psoriatic arthritis: a systematic literature research informing the 2023 update of the EULAR recommendations for the management of psoriatic arthritis. Annals of the rheumatic diseases 83 (6) (2024)
Laure Gossec, Andreas Kerschbaumer, Ricardo Jorge de Oliveira Ferreira, Daniel Aletaha, Xenofon Baraliakos, Heidi Bertheussen, Wolf-Henning Boehncke, Bente Appel Esbensen, Iain B McInnes, Dennis McGonagle, Kevin L Winthrop, Andra Balanescu, Peter V Balint, Gerd-Rüdiger R Burmester, Juan D Cañete, Pascal Claudepierre, Lihi Eder, Merete Lund Hetland, AnnaMaria Iagnocco, Lars Erik Kristensen, Rik Lories, Rubén Queiro, Daniele Mauro, Helena Marzo-Ortega, Phillip J Mease, Peter Nash, Wendy Wagenaar, Laura Savage, Larissa Valor-Méndez, Stephanie J W Shoop-Worrall, Yoshiya Tanaka, Filip E Van den Bosch, Annette van der Helm-van Mil, Alen Zabotti, Désirée Mfm van der Heijde, Josef S Smolen
EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update. Annals of the rheumatic diseases (2024)
Andreas Kerschbaumer, Josef S Smolen, Ricardo Jorge de Oliveira Ferreira, Heidi Bertheussen, Xenofon Baraliakos, Daniel Aletaha, Dennis G McGonagle, Désirée Mfm van der Heijde, Iain B McInnes, Bente Appel Esbensen, Kevin L Winthrop, Wolf-Henning Boehncke, Johan A F Koekkoek, Laure Gossec
Efficacy and safety of pharmacological treatment of psoriatic arthritis: a systematic literature research informing the 2023 update of the EULAR recommendations for the management of psoriatic arthritis. Annals of the rheumatic diseases (2024)
Gerd-Rüdiger R Burmester, Jacques-Eric Gottenberg, Roberto Felice Caporali, Kevin L Winthrop, Yoshiya Tanaka, Edmund V Ekoka Omoruyi, Vijay Rajendran, Paul Van Hoek, Katrien Van Beneden, Tsutomu Takeuchi, René Westhovens, Daniel Aletaha
Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years. Annals of the rheumatic diseases 83 (9) (2024)
Laure Gossec, Andreas Kerschbaumer, Ricardo Jorge de Oliveira Ferreira, Daniel Aletaha, Xenofon Baraliakos, Heidi Bertheussen, Wolf-Henning Boehncke, Bente Appel Esbensen, Iain B McInnes, Dennis McGonagle, Kevin L Winthrop, Andra Balanescu, Peter V Balint, Gerd-Rüdiger R Burmester, Juan D Cañete, Pascal Claudepierre, Lihi Eder, Merete Lund Hetland, AnnaMaria Iagnocco, Lars Erik Kristensen, Rik Lories, Rubén Queiro, Daniele Mauro, Helena Marzo-Ortega, Phillip J Mease, Peter Nash, Wendy Wagenaar, Laura Savage, Larissa Valor-Méndez, Stephanie J W Shoop-Worrall, Yoshiya Tanaka, Filip E Van den Bosch, Annette van der Helm-van Mil, Alen Zabotti, Désirée Mfm van der Heijde, Josef S Smolen
EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update. Annals of the rheumatic diseases 83 (6) (2024)
Bita Shakoory, Ashley Geerlinks, Marta Wilejto, Kate Kernan, Melissa Hines, Micol Romano, David Piskin, Angelo Ravelli, Rashmi Sinha, Daniel Aletaha, Carl Allen, Hamid Bassiri, Edward M Behrens, Joseph Carcillo, Linda Carl, Winn Chatham, Jeffrey I Cohen, Randy Q Cron, Erik Drewniak, Alexei A Grom, Lauren A Henderson, Annacarin Horne, Michael B Jordan, Kim E Nichols, Grant S Schulert, Sebastiaan Vastert, Erkan Demirkaya, Raphaela Goldbach-Mansky, Fabrizio de Benedetti, Rebecca A Marsh, Scott W Canna, null null
The 2022 EULAR/ACR points to consider at the early stages of diagnosis and management of suspected haemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS). Annals of the rheumatic diseases (2023)
Marianne A Messelink, Alfons A den Broeder, Florine E Marinelli, Edwin Michgels, Patrick Verschueren, Daniel Aletaha, Janneke Tekstra, Paco M J Welsing
What is the best target in a treat-to-target strategy in rheumatoid arthritis? Results from a systematic review and meta-regression analysis. RMD open 9 (2) (2023)
Kevin L Winthrop, John Dudley Isaacs, Phillip J Mease, Dimitrios T Boumpas, Xenofon Baraliakos, Jacques-Eric Gottenberg, Stefan Siebert, Marta Mosca, Neil Basu, Dana Orange, R Lories, Daniel Aletaha, Iain B McInnes, Thomas Wj Huizinga, Reinhard E Voll, Ellen M Gravallese, Ferry C Breedveld, Josef S Smolen
Unmet need in rheumatology: reports from the Advances in Targeted Therapies meeting, 2022. Annals of the rheumatic diseases (2023)
Alen Zabotti, Gabriele De Marco, Laure Gossec, Xenofon Baraliakos, Daniel Aletaha, AnnaMaria Iagnocco, Paolo Gisondi, Peter V Balint, Heidi Bertheussen, Wolf-Henning Boehncke, Nemanja S Damjanov, Maarten P T de Wit, Enzo Errichetti, Helena Marzo-Ortega, Mikhail Protopopov, Lluis Puig, Rubén Queiro, Roberto Caporali, Laura Savage, Larissa Valor-Méndez, Stefan Siebert, Tanja Alexandra Stamm, Paul Studenic, Ilaria Tinazzi, Filip E Van den Bosch, Annette van der Helm-van Mil, Giovanni Damiani, Josef S Smolen, Dennis G McGonagle
EULAR points to consider for the definition of clinical and imaging features suspicious for progression from psoriasis to psoriatic arthritis. Annals of the rheumatic diseases (2023)
Maximilian Kugler, Mirjam Dellinger, Felix Kartnig, Lena Müller, Teresa Preglej, Leonhard X Heinz, Elisabeth Simader, Lisa Göschl, Stephan E Puchner, Sebastian Weiss, Lisa E Shaw, Matthias Farlik, Wolfgang Weninger, Giulio Superti-Furga, Josef S Smolen, Guenter Steiner, Daniel Aletaha, Hans P Kiener, Myles J Lewis, Costantino Pitzalis, Anela Tosevska, Thomas Karonitsch, Michael Markus Bonelli
Cytokine-directed cellular cross-talk imprints synovial pathotypes in rheumatoid arthritis. Annals of the rheumatic diseases (2023)
Michael Markus Bonelli, Andreas Kerschbaumer, Kastriot Kastrati, Kamran Ghoreschi, Massimo Gadina, Leonhard X Heinz, Josef S Smolen, Daniel Aletaha, John O'Shea, Arian Laurence
Selectivity, efficacy and safety of JAKinibs: new evidence for a still evolving story. Annals of the rheumatic diseases (2023)
Kevin L Winthrop, John Dudley Isaacs, Phillip J Mease, Dimitrios T Boumpas, Xenofon Baraliakos, Jacques-Eric Gottenberg, Stefan Siebert, Marta Mosca, Neil Basu, Dana Orange, R Lories, Daniel Aletaha, Iain B McInnes, Thomas Wj Huizinga, Reinhard E Voll, Ellen M Gravallese, Ferry C Breedveld, Josef S Smolen
Unmet need in rheumatology: reports from the Advances in Targeted Therapies meeting, 2022. Annals of the rheumatic diseases (2023)
Daniel Aletaha
Polymyalgia Rheumatica - from Search for Efficacy to Choice of Strategy. The New England journal of medicine 389 (14) (2023)
Gabriele de Marco, Alen Zabotti, Xenofon Baraliakos, AnnaMaria Iagnocco, Daniel Aletaha, Paulo Gisondi, Jenny Emmel, Josef S Smolen, Dennis G McGonagle, Laure Gossec
Characterisation of prodromal and very early psoriatic arthritis: a systematic literature review informing a EULAR taskforce. RMD open 9 (2) (2023)
Marianne A Messelink, Alfons A den Broeder, Florine E Marinelli, Edwin Michgels, Patrick Verschueren, Daniel Aletaha, Janneke Tekstra, Paco M J Welsing
What is the best target in a treat-to-target strategy in rheumatoid arthritis? Results from a systematic review and meta-regression analysis. RMD open 9 (2) (2023)
Paul Studenic, Daniel Aletaha, Tanja Alexandra Stamm, Maarten P T de Wit, Diane Lacaille, Josef S Smolen, David T Felson
Response to: Correspondence on "Testing different thresholds for patient global assessment in defining remission for rheumatoid arthritis: are the current ACR/EULAR Boolean criteria optimal?" by Studenic et al . Annals of the rheumatic diseases (2023)
Gabriele de Marco, Alen Zabotti, Xenofon Baraliakos, AnnaMaria Iagnocco, Daniel Aletaha, Paulo Gisondi, Jenny Emmel, Josef S Smolen, Dennis G McGonagle, Laure Gossec
Characterisation of prodromal and very early psoriatic arthritis: a systematic literature review informing a EULAR taskforce. RMD open 9 (2) (2023)
Mathias Schneeweiss-Gleixner, Caroline Hillebrand, Stephanie Jaksits, Jonathan Fries, Michael Zauner, Gottfried Heinz, Gürkan Sengölge, Thomas Staudinger, Christian Zauner, Daniel Aletaha, Klaus P Machold, Peter Schellongowski, Manuel Bécède
Characteristics and outcome of critically ill patients with systemic rheumatic diseases referred to the intensive care unit. RMD open 9 (4) (2023)
Victoria Konzett, Andreas Kerschbaumer, Josef S Smolen, Eirik Klami Kristianslund, Sella Aarrestad Provan, Tore K Kvien, Daniel Aletaha
Definition of rheumatoid arthritis flare based on SDAI and CDAI. Annals of the rheumatic diseases (2023)
Paul Studenic, Daniel Aletaha, Tanja Alexandra Stamm, Maarten P T de Wit, Diane Lacaille, Josef S Smolen, David T Felson
Response to: Correspondence on "Testing different thresholds for patient global assessment in defining remission for rheumatoid arthritis: are the current ACR/EULAR Boolean criteria optimal?" by Studenic et al . Annals of the rheumatic diseases (2023)
Andreas Kerschbaumer, Nina Maria Stimakovits, Josef S Smolen, Tijen Stefanova, Eva Chwala, Daniel Aletaha
Influence of active versus placebo control on treatment responses in randomised controlled trials in rheumatoid arthritis. Annals of the rheumatic diseases (2023)
Marianne A Messelink, Alfons A den Broeder, Florine E Marinelli, Edwin Michgels, Patrick Verschueren, Daniel Aletaha, Janneke Tekstra, Paco M J Welsing
What is the best target in a treat-to-target strategy in rheumatoid arthritis? Results from a systematic review and meta-regression analysis. RMD open 9 (2) (2023)
Paul Studenic, Daniel Aletaha, Tanja Alexandra Stamm, Maarten P T de Wit, Diane Lacaille, Josef S Smolen, David T Felson
Response to: Correspondence on "Testing different thresholds for patient global assessment in defining remission for rheumatoid arthritis: are the current ACR/EULAR Boolean criteria optimal?" by Studenic et al . Annals of the rheumatic diseases (2023)
Christian Dejaco, Andreas Kerschbaumer, Daniel Aletaha, Milena Bond, Elvis Hysa, Dario Camellino, Lisa Ehlers, Andy Abril, Simone Appenzeller, Maria Cinta Cid, Bhaskar Dasgupta, Christina Duftner, Peter C Grayson, Bernhard Hellmich, Alojzija Hocevar, Tanaz A Kermani, Eric L Matteson, Susan P Mollan, Lorna Neill, Cristina Ponte, Carlo Salvarani, Sebastian Eduardo Sattui, Wolfgang Andreas Schmidt, Philip Seo, Josef S Smolen, Jens Thiel, Carlos Enrique Toro Gutiérrez, Madeline Whitlock, Frank Buttgereit
Treat-to-target recommendations in giant cell arteritis and polymyalgia rheumatica. Annals of the rheumatic diseases (2023)
Andras Boeszoermenyi, Léa Bernaleau, Xudong Chen, Felix Kartnig, Min Xie, Haobo Zhang, Sensen Zhang, Maeva Delacrétaz, Anna Koren, Ann-Katrin Hopp, Vojtech Dvorak, Stefan Kubicek, Daniel Aletaha, Maojun Yang, Manuele Rebsamen, Leonhard X Heinz, Giulio Superti-Furga
A conformation-locking inhibitor of SLC15A4 with TASL proteostatic anti-inflammatory activity. Nature communications 14 (1) (2023)
Céleste J T van der Togt, Bart Van den Bemt, Daniel Aletaha, Rieke E Alten, Katerina Chatzidionysiou, James B Galloway, John Isaac, Denis Mulleman, Patrick Verschueren, Arnold G Vulto, Paco M J Welsing, Lise Verhoef, Alfons A den Broeder
Points to consider for cost-effective use of biological and targeted synthetic DMARDs in inflammatory rheumatic diseases: results from an umbrella review and international Delphi study. RMD open 9 (1) (2023)
Victoria Konzett, Andreas Kerschbaumer, Josef S Smolen, Daniel Aletaha
Determination of the most appropriate ACR response definition for contemporary drug approval trials in rheumatoid arthritis. Annals of the rheumatic diseases (2023)
Kevin L Winthrop, John Dudley Isaacs, Phillip J Mease, Dimitrios T Boumpas, Xenofon Baraliakos, Jacques-Eric Gottenberg, Stefan Siebert, Marta Mosca, Neil Basu, Dana Orange, R Lories, Daniel Aletaha, Iain B McInnes, Thomas Wj Huizinga, Reinhard E Voll, Ellen M Gravallese, Ferry C Breedveld, Josef S Smolen
Unmet need in rheumatology: reports from the Advances in Targeted Therapies meeting, 2022. Annals of the rheumatic diseases (2023)
Antonia Puchner, Elisabeth Simader, Victoria Saferding, Melanie Hofmann, Markus Kieler, Julia Brunner, René Pfeifle, Birgit Niederreiter, Gerhard Krönke, Gernot Schabbauer, Philippe Georgel, Gretchen Diehl, Guenter Steiner, Silvia Hayer, Kurt Redlich, Josef S Smolen, Daniel Aletaha, Stephan Blüml
Bona fide dendritic cells are pivotal precursors for osteoclasts. Annals of the rheumatic diseases (2023)
Céleste J T van der Togt, Bart Van den Bemt, Daniel Aletaha, Rieke E Alten, Katerina Chatzidionysiou, James B Galloway, John Isaac, Denis Mulleman, Patrick Verschueren, Arnold G Vulto, Paco M J Welsing, Lise Verhoef, Alfons A den Broeder
Points to consider for cost-effective use of biological and targeted synthetic DMARDs in inflammatory rheumatic diseases: results from an umbrella review and international Delphi study. RMD open 9 (1) (2023)
Marianne A Messelink, Alfons A den Broeder, Florine E Marinelli, Edwin Michgels, Patrick Verschueren, Daniel Aletaha, Janneke Tekstra, Paco M J Welsing
What is the best target in a treat-to-target strategy in rheumatoid arthritis? Results from a systematic review and meta-regression analysis. RMD open 9 (2) (2023)
Markus M Schreiner, Jennifer Straub, Sebastian Apprich, Kevin Staats, Reinhard Windhager, Daniel Aletaha, Christoph Böhler
The influence of biological DMARDs on aseptic arthroplasty loosening-a retrospective cohort study. Rheumatology (Oxford, England) (2023)
Céleste J T van der Togt, Bart Van den Bemt, Daniel Aletaha, Rieke E Alten, Katerina Chatzidionysiou, James B Galloway, John Isaac, Denis Mulleman, Patrick Verschueren, Arnold G Vulto, Paco M J Welsing, Lise Verhoef, Alfons A den Broeder
Points to consider for cost-effective use of biological and targeted synthetic DMARDs in inflammatory rheumatic diseases: results from an umbrella review and international Delphi study. RMD open 9 (1) (2023)
Paul Studenic, Daniel Aletaha, Tanja Alexandra Stamm, Maarten P T de Wit, Diane Lacaille, Josef S Smolen, David T Felson
Response to: Correspondence on "Testing different thresholds for patient global assessment in defining remission for rheumatoid arthritis: are the current ACR/EULAR Boolean criteria optimal?" by Studenic et al . Annals of the rheumatic diseases (2023)
Kevin L Winthrop, Philip Mease, Andreas Kerschbaumer, Reinhard E Voll, Ferdinand C Breedveld, Josef S Smolen, Jacques-Eric Gottenberg, Xenofon Baraliakos, Hans P Kiener, Daniel Aletaha, John Dudley Isaacs, Maya H Buch, Mary K Crow, Jonathan Kay, Leslie J Crofford, Ronald F Van Vollenhoven, Caroline Ospelt, Stefan Siebert, Margreet Kloppenburg, Iain B McInnes, Thomas Wj Huizinga, Ellen M Gravallese
Unmet need in rheumatology: reports from the Advances in Targeted Therapies meeting, 2023. Annals of the rheumatic diseases (2023)
Céleste J T van der Togt, Bart Van den Bemt, Daniel Aletaha, Rieke E Alten, Katerina Chatzidionysiou, James B Galloway, John Isaac, Denis Mulleman, Patrick Verschueren, Arnold G Vulto, Paco M J Welsing, Lise Verhoef, Alfons A den Broeder
Points to consider for cost-effective use of biological and targeted synthetic DMARDs in inflammatory rheumatic diseases: results from an umbrella review and international Delphi study. RMD open 9 (1) (2023)
Kastriot Kastrati, Daniel Aletaha, Gerd-Rüdiger R Burmester, Eva Chwala, Christian Dejaco, Maxime Dougados, Iain B McInnes, Angelo Ravelli, Naveed Sattar, Tanja Alexandra Stamm, Tsutomu Takeuchi, Michael Trauner, Désirée Mfm van der Heijde, Marieke J H Voshaar, Kevin L Winthrop, Josef S Smolen, Andreas Kerschbaumer
A systematic literature review informing the consensus statement on efficacy and safety of pharmacological treatment with interleukin-6 pathway inhibition with biological DMARDs in immune-mediated inflammatory diseases. RMD open 8 (2) (2022)
Alessia Alunno, Felice Rivellese, Kim Lauper, Daniel Aletaha, Maya H Buch, Laure Gossec, Peter Mandl, Pedro M Machado, Caroline Ospelt, Anna Moltó, Sofia Ramiro, Elena Nikiphorou, Alexandre Sepriano
EMerging EULAR NETwork (EMEUNET): a remarkable foundation for the future. RMD open 7 (3) (2022)
Carina Borst, Farideh Alasti, Josef S Smolen, Daniel Aletaha
Role of clinical and biochemical inflammation in structural progression of patients with psoriatic arthritis. RMD open 7 (3) (2022)
Iain B McInnes, AnnaMaria Iagnocco, Daniel Aletaha, Xenofon Baraliakos, Johannes W J Bijlsma, Elsa F Mateus, Zoltán Szekanecz, Thea P M Vliet Vlieland, Josef S Smolen
Reflections on a contemporary European tragedy. Annals of the rheumatic diseases 81 (6) (2022)
Lieve VAN Hoovels, Lucy Studholme, Bert Vander Cruyssen, Daniela Sieghart, Carolien Bonroy, Eszter Nagy, Rille Pullerits, Sasa Čučnik, Charlotte Dahle, Ingmar Heijnen, Luca Bernasconi, Farid Benkhadra, Laura Bogaert, Stefanie Van Den Bremt, Ann Van Liedekerke, Geert Vanheule, Johan Robbrecht, Claudine Wirth, Rüdiger Müller, Diego Kyburz, Christopher Sjöwall, Alf Kastbom, Rok Ješe, Boja Jovancevic, Emese Kiss, Peggy Jacques, Daniel Aletaha, Günter Steiner, Patrick Verschueren, Xavier Bossuyt
Standardisation of ACPA tests: evaluation of a new candidate reference preparation. Annals of the rheumatic diseases (2022)
Peter Mandl, Selma Tobudic, Helmut Haslacher, Thomas Karonitsch, Daniel Mrak, Thomas Nothnagl, Thomas Perkmann, Helga Radner, Judith Sautner, Elisabeth Simader, Florian Winkler, Heinz Burgmann, Daniel Aletaha, Stefan Winkler, Stephan Blüml
Response to SARS-CoV-2 vaccination in systemic autoimmune rheumatic disease depends on immunosuppressive regimen: a matched, prospective cohort study. Annals of the rheumatic diseases 81 (7) (2022)
Daniel Aletaha, Andreas Kerschbaumer, Kastriot Kastrati, Christian Dejaco, Maxime Dougados, Iain B McInnes, Naveed Sattar, Tanja Alexandra Stamm, Tsutomu Takeuchi, Michael Trauner, Désirée Mfm van der Heijde, Marieke Voshaar, Kevin L Winthrop, Angelo Ravelli, Neil Betteridge, Gerd-Rüdiger R Burmester, Johannes W J Bijlsma, Vivian Bykerk, Roberto Caporali, Ernest H S Choy, Catalin Codreanu, Bernard Combe, Mary K Crow, Maarten P T de Wit, Paul Emery, Roy M Fleischmann, Cem Gabay, Merete Lund Hetland, Kimmie L Hyrich, AnnaMaria Iagnocco, John Dudley Isaacs, Joel M Kremer, Xavier Mariette, Peter A Merkel, Eduardo F Mysler, Peter Nash, Michael T Nurmohamed, Karel Pavelka, Gyula Poor, Andrea Rubbert-Roth, Hendrik Schulze-Koops, Anja Strangfeld, Yoshiya Tanaka, Josef S Smolen
Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an update. Annals of the rheumatic diseases (2022)
Micol Romano, Z Serap Arici, David Piskin, Sara Alehashemi, Daniel Aletaha, Karyl Barron, Susanne Benseler, Roberta A Berard, Lori Broderick, Fatma Dedeoğlu, Michelle Diebold, Karen Durrant, Polly Ferguson, Dirk Foell, Jonathan S Hausmann, Olcay Y Jones, Daniel Kastner, Helen J Lachmann, Ronald M Laxer, Dorelia Rivera, Nicolino Ruperto, Anna Simon, Marinka Twilt, Joost Frenkel, Hal M Hoffman, Adriana A de Jesus, Jasmin Beate Kuemmerle-Deschner, Seher Sener, Marco Gattorno, Raphaela Goldbach Mansky, Erkan Demirkaya
The 2021 EULAR/American College of Rheumatology Points to Consider for Diagnosis, Management and Monitoring of the Interleukin-1 Mediated Autoinflammatory Diseases: Cryopyrin-Associated Periodic Syndromes, Tumour Necrosis Factor Receptor-Associated Periodic Syndrome, Mevalonate Kinase Deficiency, and Deficiency of the Interleukin-1 Receptor Antagonist. Arthritis & rheumatology (Hoboken, N.J.) 74 (7) (2022)
Kader Cetin Gedik, Lovro Lamot, Micol Romano, Erkan Demirkaya, David Piskin, Sofia Torreggiani, Laura A Adang, Thais Armangue, Kathe Barchus, Devon R Cordova, Yanick J Crow, Russell C Dale, Karen L Durrant, Despina Eleftheriou, Elisa M Fazzi, Marco Gattorno, Francesco Gavazzi, Eric P Hanson, Min Ae Lee-Kirsch, Gina A Montealegre Sanchez, Bénédicte Neven, Simona Orcesi, Seher Sener, M Cecilia Poli, Elliot Schumacher, Davide Tonduti, Katsiaryna Uss, Daniel Aletaha, Brian M Feldman, Adeline Vanderver, Paul A Brogan, Raphaela Goldbach Mansky
The 2021 European Alliance of Associations for Rheumatology/American College of Rheumatology points to consider for diagnosis and management of autoinflammatory type I interferonopathies: CANDLE/PRAAS, SAVI and AGS. Annals of the rheumatic diseases 81 (5) (2022)
Daniel Mrak, Elisabeth Simader, Daniela Sieghart, Peter Mandl, Helga Radner, Thomas Perkmann, Helmuth Haslacher, Margareta Mayer, Maximilian Koblischke, Philipp Hofer, Lisa Göschl, Felix Kartnig, Thomas Deimel, Andreas Kerschbaumer, Thomas Hummel, Barbara Kornek, Renate Thalhammer, Karin Stiasny, Stefan Winkler, Josef S Smolen, Judith H Aberle, Daniel Aletaha, Leonhard X Heinz, Michael Markus Bonelli
Immunogenicity and safety of a fourth COVID-19 vaccination in rituximab-treated patients: an open-label extension study. Annals of the rheumatic diseases 81 (12) (2022)
Lieve VAN Hoovels, Bert Vander Cruyssen, Daniela Sieghart, Carolien Bonroy, Eszter Nagy, Rille Pullerits, Saša Čučnik, Charlotte Dahle, Ingmar Heijnen, Luca Bernasconi, Farid Benkhadra, Laura Bogaert, Stefanie Van Den Bremt, Ann Van Liedekerke, Geert Vanheule, Johan Robbrecht, Lucy Studholme, Claudine Wirth, Ruediger B Mueller, Diego Kyburz, Christopher Sjöwall, Alf Kastbom, Rok Ješe, Boja Jovancevic, Emese Kiss, Peggy Jacques, Daniel Aletaha, Guenter Steiner, Patrick Verschueren, Xavier Bossuyt
Multicentre study to improve clinical interpretation of rheumatoid factor and anti-citrullinated protein/peptide antibodies test results. RMD open 8 (1) (2022)
Paul Studenic, Daniel Aletaha, Maarten P T de Wit, Tanja Alexandra Stamm, Farideh Alasti, Diane Lacaille, Josef S Smolen, David T Felson
American College of Rheumatology/EULAR remission criteria for rheumatoid arthritis: 2022 revision. Annals of the rheumatic diseases (2022)
Daniel Aletaha
The undifferentiated arthritis dilemma: the story continues. Nature reviews. Rheumatology 18 (4) (2022)
Josef S Smolen, Robert B M Landewe, Sytske Anne Bergstra, Andreas Kerschbaumer, Alexandre Sepriano, Daniel Aletaha, Roberto Caporali, Christopher John Edwards, Kimmie L Hyrich, Janet E Pope, Savia de Souza, Tanja Alexandra Stamm, Tsutomu Takeuchi, Patrick Verschueren, Kevin L Winthrop, Alejandro Balsa, Joan M Bathon, Maya H Buch, Gerd-Rüdiger R Burmester, Frank Buttgereit, Mario Humberto Cardiel, Katerina Chatzidionysiou, Catalin Codreanu, Maurizio Cutolo, Alfons A den Broeder, Khadija El Aoufy, Axel Finckh, João Eurico Fonseca, Jacques-Eric Gottenberg, Espen A Haavardsholm, AnnaMaria Iagnocco, Kim Lauper, Zhanguo Li, Iain B McInnes, Eduardo F Mysler, Peter Nash, Gyula Poor, Gorica G Ristic, Felice Rivellese, Andrea Rubbert-Roth, Hendrik Schulze-Koops, Nikolay Stoilov, Anja Strangfeld, Annette van der Helm-van Mil, Elsa van Duuren, Thea P M Vliet Vlieland, René Westhovens, Désirée Mfm van der Heijde
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Annals of the rheumatic diseases (2022)
Thomas Karonitsch, Lusine Yeghiazaryan, Angelika Lackner, Hans Peter Brezinsek, Tanja Alexandra Stamm, Franz König, Daniel Aletaha, Josef S Smolen
Targeting type I interferon (IFN) signalling in patients with RA with a high type I IFN gene signature. RMD open 8 (2) (2022)
Pedro López-Romero, Inmaculada de la Torre, Ewa Haladyj, Daniel Aletaha, Josef S Smolen
Baricitinib further enhances disease-modifying effects by uncoupling the link between disease activity and joint structural progression in patients with rheumatoid arthritis. Annals of the rheumatic diseases 81 (5) (2022)
David T Felson, Diane Lacaille, Michael P LaValley, Daniel Aletaha
Response to: Correspondence on 'Re-examining remission definitions in rheumatoid arthritis: considering the 28-Joint Disease Activity Score, C-reactive protein level and patient global assessment' by Felson et al . Annals of the rheumatic diseases (2022)
Sytske Anne Bergstra, Alexandre Sepriano, Andreas Kerschbaumer, Désirée Mfm van der Heijde, Roberto Caporali, Christopher John Edwards, Patrick Verschueren, Savia de Souza, Janet E Pope, Tsutomu Takeuchi, Kimmie L Hyrich, Kevin L Winthrop, Daniel Aletaha, Tanja Alexandra Stamm, Johan A F Koekkoek, Josef S Smolen, Robert B M Landewe
Efficacy, duration of use and safety of glucocorticoids: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis. Annals of the rheumatic diseases (2022)
David Piskin, Micol Romano, Daniel Aletaha, Brian M Feldman, Raphaela Goldbach-Mansky, Loreto Carmona, Erkan Demirkaya
Developing guidelines for ultrarare rheumatic disorders: a bumpy ride. Annals of the rheumatic diseases (2022)
David T Felson, Diane Lacaille, Michael P LaValley, Daniel Aletaha
Reexamining remission definitions in rheumatoid arthritis: considering the twenty-eight-joint Disease Activity Score, C-reactive protein level and patient global assessment. RMD open 7 (3) (2022)
Michael Markus Bonelli, Daniel Mrak, Selma Tobudic, Daniela Sieghart, Maximilian Koblischke, Peter Mandl, Barbara Kornek, Elisabeth Simader, Helga Radner, Thomas Perkmann, Helmuth Haslacher, Margareta Mayer, Philipp Hofer, Kurt Redlich, Emma Husar-Memmer, Ruth Fritsch-Stork, Renate Thalhammer, Karin Stiasny, Stefan Winkler, Josef S Smolen, Judith H Aberle, Markus Zeitlinger, Leonhard X Heinz, Daniel Aletaha
Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: a randomised controlled trial. Annals of the rheumatic diseases 81 (5) (2022)
Micol Romano, Z Serap Arici, David Piskin, Sara Alehashemi, Daniel Aletaha, Karyl S Barron, Susanne Benseler, Roberta Berard, Lori Broderick, Fatma Dedeoglu, Michelle Diebold, Karen L Durrant, Polly Ferguson, Dirk Foell, Jonathan S Hausmann, Olcay Y Jones, Daniel L Kastner, Helen J Lachmann, Ronald M Laxer, Dorelia Rivera, Nicolino Ruperto, Anna Simon, Marinka Twilt, Joost Frenkel, Hal Hoffman, Adriana A de Jesus, Jasmin Beate Kuemmerle-Deschner, Seher Sener, Marco Gattorno, Raphaela Goldbach Mansky, Erkan Demirkaya
The 2021 EULAR/American College of Rheumatology points to consider for diagnosis, management and monitoring of the interleukin-1 mediated autoinflammatory diseases: cryopyrin-associated periodic syndromes, tumour necrosis factor receptor-associated periodic syndrome, mevalonate kinase deficiency, and deficiency of the interleukin-1 receptor antagonist. Annals of the rheumatic diseases 81 (7) (2022)
Alexandre Sepriano, Andreas Kerschbaumer, Sytske Anne Bergstra, Josef S Smolen, Désirée Mfm van der Heijde, Roberto Caporali, Christopher J Edwards, Patrick Verschueren, Savia de Souza, Janet E Pope, Tsutomu Takeuchi, Kimmie L Hyrich, Kevin L Winthrop, Daniel Aletaha, Tanja Alexandra Stamm, Johan A F Koekkoek, Robert B M Landewe
Safety of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis. Annals of the rheumatic diseases (2022)
Felix Kartnig, Daniel Mrak, Elisabeth Simader, Selma Tobudic, Helga Radner, Peter Mandl, Lisa Göschl, Nikolaus Hommer, Margareta Mayer, Philipp Hofer, Thomas Hummel, Thomas Deimel, Irina Geßl, Antonia Puchner, Andreas Kerschbaumer, Renate Thalhammer, Alessandra Handisurya, Renate Kain, Stefan Winkler, Josef S Smolen, Karin Stiasny, Thomas Perkmann, Helmuth Haslacher, Judith H Aberle, Daniel Aletaha, Leonhard X Heinz, Daniela Sieghart, Michael Markus Bonelli
Safety and immunogenicity of a third COVID-19 vaccination in patients with immune-mediated inflammatory diseases compared with healthy controls. Annals of the rheumatic diseases (2022)
Andreas Kerschbaumer, Zaïda Iasha Rivai, Josef S Smolen, Daniel Aletaha
Impact of pre-existing background therapy on placebo responses in randomised controlled clinical trials of rheumatoid arthritis. Annals of the rheumatic diseases 81 (10) (2022)
Kader Cetin Gedik, Lovro Lamot, Micol Romano, Erkan Demirkaya, David Piskin, Sofia Torreggiani, Laura A Adang, Thais Armangue, Kathe Barchus, Devon R Cordova, Yanick J Crow, Russell C Dale, Karen L Durrant, Despina Eleftheriou, Elisa M Fazzi, Marco Gattorno, Francesco Gavazzi, Eric P Hanson, Min Ae Lee-Kirsch, Gina A Montealegre Sanchez, Bénédicte Neven, Simona Orcesi, Seher Sener, M Cecilia Poli, Elliot Schumacher, Davide Tonduti, Katsiaryna Uss, Daniel Aletaha, Brian M Feldman, Adeline Vanderver, Paul A Brogan, Raphaela Goldbach Mansky
The 2021 European Alliance of Associations for Rheumatology/American College of Rheumatology Points to Consider for Diagnosis and Management of Autoinflammatory Type I Interferonopathies: CANDLE/PRAAS, SAVI, and AGS. Arthritis & rheumatology (Hoboken, N.J.) 74 (5) (2022)
Daniel Mrak, Daniela Sieghart, Elisabeth Simader, Selma Tobudic, Helga Radner, Peter Mandl, Lisa Göschl, Maximilian Koblischke, Nikolaus Hommer, Angelika Wagner, Margareta Mayer, Lorenz Schubert, Lukas Hartl, Karin Kozbial, Philipp Hofer, Felix Kartnig, Thomas Hummel, Andreas Kerschbaumer, Thomas Deimel, Antonia Puchner, Venugopal Gudipati, Renate Thalhammer, Petra Munda, Keziban Uyanik-Ünal, Andreas Zuckermann, Gottfried Novacek, Thomas Reiberger, Erika Garner-Spitzer, Roman Reindl-Schwaighofer, Renate Kain, Stefan Winkler, Josef S Smolen, Karin Stiasny, Gottfried F Fischer, Thomas Perkmann, Helmuth Haslacher, Markus Zeitlinger, Ursula Wiedermann, Judith H Aberle, Daniel Aletaha, Leonhard X Heinz, Michael Markus Bonelli
Heterologous vector versus homologous mRNA COVID-19 booster vaccination in non-seroconverted immunosuppressed patients: a randomized controlled trial. Nature communications 13 (1) (2022)
Andreas Kerschbaumer, Alexandre Sepriano, Sytske Anne Bergstra, Josef S Smolen, Désirée Mfm van der Heijde, Roberto Caporali, Christopher John Edwards, Patrick Verschueren, Savia de Souza, Janet E Pope, Tsutomu Takeuchi, Kimmie L Hyrich, Kevin L Winthrop, Daniel Aletaha, Tanja Alexandra Stamm, Johan A F Koekkoek, Robert B M Landewe
Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis. Annals of the rheumatic diseases (2022)
Michael Markus Bonelli, Helga Radner, Andreas Kerschbaumer, Daniel Mrak, Martina Durechova, Jutta Stieger, Rusmir Husic, Peter Mandl, Josef S Smolen, Christian Dejaco, Daniel Aletaha
Tocilizumab in patients with new onset polymyalgia rheumatica (PMR-SPARE): a phase 2/3 randomised controlled trial. Annals of the rheumatic diseases 81 (6) (2022)
Irina Gessl, Claudia A Hana, Thomas Deimel, Martina Durechova, Miriam Hucke, Victoria Konzett, Mihaela Popescu, Paul Studenic, Gabriela Supp, Michael Zauner, Josef S Smolen, Daniel Aletaha, Peter Mandl
Tenderness and radiographic progression in rheumatoid arthritis and psoriatic arthritis. Annals of the rheumatic diseases (2022)
Manuel Kussmann, Markus Obermueller, Kathrin Spettel, Stefan Winkler, Daniel Aletaha
In vitro evaluation of disease-modifying antirheumatic drugs against rheumatoid arthritis associated pathogens of the oral microflora. RMD open 7 (3) (2021)
Dennis G McGonagle, Alen Zabotti, Giovanni Damiani, Charlie Bridgewood, Gabriele De Marco, Andreas Kerschbaumer, Daniel Aletaha
Intercepting psoriatic arthritis in patients with psoriasis: buy one get one free? Annals of the rheumatic diseases (2021)
Daniel Aletaha, René Westhovens, Cecile Gaujoux-Viala, Giovanni Adami, Alan Matsumoto, Paul Bird, Osvaldo Daniel Messina, Maya H Buch, Beatrix Bartok, Zhaoyu Yin, Ying Guo, Thijs Hendrikx, Gerd-Rüdiger R Burmester
Efficacy and safety of filgotinib in methotrexate-naive patients with rheumatoid arthritis with poor prognostic factors: post hoc analysis of FINCH 3. RMD open 7 (2) (2021)
David T Felson, Diane Lacaille, Michael P LaValley, Daniel Aletaha
Re-examining remission definitions in rheumatoid arthritis: considering the 28-Joint Disease Activity Score, C-reactive protein level and patient global assessment. Annals of the rheumatic diseases (2021)
Elisabeth Simader, Selma Tobudic, Peter Mandl, Helmuth Haslacher, Thomas Perkmann, Thomas Nothnagl, Judith Sautner, Helga Radner, Florian Winkler, Heinz Burgmann, Daniel Mrak, Daniel Aletaha, Stefan Winkler, Stephan Blüml
Importance of the second SARS-CoV-2 vaccination dose for achieving serological response in patients with rheumatoid arthritis and seronegative spondyloarthritis. Annals of the rheumatic diseases (2021)
Heidi J Siddle, Lara S Chapman, Kulveer Mankia, Codruța Zăbălan, Marios Kouloumas, Karim Raza, Marie Falahee, Joel Kerry, Andreas Kerschbaumer, Daniel Aletaha, Paul Emery, Suzanne H Richards
Perceptions and experiences of individuals at-risk of rheumatoid arthritis (RA) knowing about their risk of developing RA and being offered preventive treatment: systematic review and thematic synthesis of qualitative studies. Annals of the rheumatic diseases (2021)
Kulveer Mankia, Heidi Siddle, Andrea Di Matteo, Deshiré Alpizar-Rodriguez, Joel Kerry, Andreas Kerschbaumer, Daniel Aletaha, Paul Emery
A core set of risk factors in individuals at risk of rheumatoid arthritis: a systematic literature review informing the EULAR points to consider for conducting clinical trials and observational studies in individuals at risk of rheumatoid arthritis. RMD open 7 (3) (2021)
György Nagy, Nadia M T Roodenrijs, Paco M J Welsing, Melinda Kedves, Attila Hamar, Marlies C van der Goes, Alison Kent, Margot Bakkers, Polina Pchelnikova, Etienne Blaas, Ladislav Senolt, Zoltán Szekanecz, Ernest H S Choy, Maxime Dougados, Johannes W G Jacobs, Rinie Geenen, Johannes W J Bijlsma, Angela Zink, Daniel Aletaha, Leonard Schoneveld, Piet van Riel, Sophie Dumas, Yeliz Prior, Elena Nikiphorou, Gianfranco Ferraccioli, Larissa Valor-Méndez, Kimmie L Hyrich, Ulf Mueller-Ladner, Raluca Bianca Dumitru, Iain B McInnes, Désirée Mfm van der Heijde, Jacob M van Laar
EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis. Annals of the rheumatic diseases (2021)
Matthew A Brown, Daniel Aletaha
Genetic risk scores in inflammatory arthritis: a new era? Nature reviews. Rheumatology 16 (10) (2021)
Daniel Mrak, Selma Tobudic, Maximilian Koblischke, Marianne Graninger, Helga Radner, Daniela Sieghart, Philipp Hofer, Thomas Perkmann, Helmuth Haslacher, Renate Thalhammer, Stefan Winkler, Stephan Blüml, Karin Stiasny, Judith H Aberle, Josef S Smolen, Leonhard X Heinz, Daniel Aletaha, Michael Markus Bonelli
SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity. Annals of the rheumatic diseases 80 (10) (2021)
Paul Studenic, Gregor Bond, Andreas Kerschbaumer, Manuel Bécède, Karel Pavelka, Dmitry Karateev, Jutta Stieger, Rudolf Puchner, Ruediger B Mueller, Elisabeth Puchhammer-Stöckl, Martina Durechova, Michaela Loiskandl, Thomas Perkmann, Martina Olejarova, Elena Luchikhina, Carl-Walter Steiner, Michael Bonelli, Josef S Smolen, Daniel Aletaha
Torque Teno Virus Quantification for Monitoring of Immunomodulation with Biological Compounds in the Treatment of Rheumatoid Arthritis. Rheumatology (Oxford, England) (2021)
Irina Gessl, Daniel Aletaha, Peter Mandl
Response to: 'Correspondence on 'Role of joint damage, malalignment and inflammation in articular tenderness in rheumatoid arthritis, psoriatic arthritis and osteoarthritis'' by Dumoulin et al. Annals of the rheumatic diseases (2021)
Michael Markus Bonelli, Daniel Mrak, Thomas Perkmann, Helmuth Haslacher, Daniel Aletaha
SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response. Annals of the rheumatic diseases 80 (10) (2021)
Irina Gessl, Mihaela Popescu, Victoria Schimpl, Gabriela Supp, Thomas Deimel, Martina Durechova, Miriam Hucke, Michaela Loiskandl, Paul Studenic, Michael Zauner, Josef S Smolen, Daniel Aletaha, Peter Mandl
Role of joint damage, malalignment and inflammation in articular tenderness in rheumatoid arthritis, psoriatic arthritis and osteoarthritis. Annals of the rheumatic diseases 80 (7) (2021)
Michael Markus Bonelli, Daniel Aletaha
Response to: 'Correspondence on 'SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response'' by Westhoff et al. Annals of the rheumatic diseases 80 (10) (2021)
Alexander Platzer, Farideh Alasti, Josef S Smolen, Daniel Aletaha, Helga Radner, Stephan Blüml
Trajectory clusters of radiographic progression in patients with rheumatoid arthritis: associations with clinical variables. Annals of the rheumatic diseases (2021)
Kulveer Mankia, Heidi J Siddle, Andreas Kerschbaumer, Deshiré Alpizar-Rodriguez, Anca Irinel Catrina, Juan D Cañete, Andrew P Cope, Claire Immediato Daien, Kevin D Deane, Hani El Gabalawy, Axel Finckh, V Michael Holers, Marios Koloumas, Francesca Ometto, Karim Raza, Condruta Zabalan, Annette H M van der Helm van Mil, Dirkjan van Schaardenburg, Daniel Aletaha, Paul Emery
EULAR points to consider for conducting clinical trials and observational studies in individuals at risk of rheumatoid arthritis. Annals of the rheumatic diseases 80 (10) (2021)
Kevin L Winthrop, Richard J Whitley, Daniel Aletaha
SARS-CoV-2 and the rheumatology patient: the last 12 months and a boost in the future. Annals of the rheumatic diseases 80 (10) (2021)
Dafne Capelusnik, Daniel Aletaha
Baseline predictors of different types of treatment success in rheumatoid arthritis. Annals of the rheumatic diseases (2021)
Michael Markus Bonelli, Daniel Aletaha
Response to: Correspondence on "SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response" by Bonelli et al. Annals of the rheumatic diseases 80 (10) (2021)
AnnaMaria Iagnocco, Daniel Aletaha, Xenofon Baraliakos, Iain B McInnes
Message from the new EULAR President and Steering Group. Annals of the rheumatic diseases 80 (10) (2021)
Valentin Ritschl, Tanja Alexandra Stamm, Daniel Aletaha, Johannes W J Bijlsma, Peter Boehm, Răzvan Gabriel Drăgoi, Emma Dures, Fernando Estevez-Lopez, Laure Gossec, AnnaMaria Iagnocco, José B Negrón, Michal Nudel, Andréa Marques, Ellen Moholt, Conni Skrubbeltrang, Bartholomeus J F van den Bemt, Kirsten K Viktil, Marieke Voshaar, Loreto Carmona, Annette de Thurah
Prevention, screening, assessing and managing of non-adherent behaviour in people with rheumatic and musculoskeletal diseases: systematic reviews informing the 2020 EULAR points to consider. RMD open 6 (3) (2021)
Daniel Aletaha, Clifton O Bingham, George Athanasios Karpouzas, Tsutomu Takeuchi, Carter Thorne, Androniki Bili, Prasheen Agarwal, Benjamin Hsu, Ravi Rao, Kurt Brown, Yoshiya Tanaka
Long-term safety and efficacy of sirukumab for patients with rheumatoid arthritis who previously received sirukumab in randomised controlled trials (SIRROUND-LTE). RMD open 7 (1) (2021)

Daniel Aletaha.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Daniel Aletaha